felzartamab, AMR and Biogen
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Technology company Cisco is among the groups involved in six virtual power purchase agreements (VPPAs) to secure energy from ...
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
The stock's fall snapped a seven-day winning streak.
Multiple Sclerosis Therapeutics market is estimated to be valued at USD 31.39 Bn in 2025 and is expected to reach USD 41.89 Bn by 2032, exhibiting a CAGR of 4%. BURLINGAME, CA, UNITED STATES, March 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback